1. Scrip
  2. >>New Products

GSK's Jemperli First-Line Endometrial Cancer Approval Fillip Ahead Of Keytruda Advance

With Restricted Label

 
• By Ayisha Sharma

The major’s PD-L1 inhibitor is the first to win US approval for the treatment of first-line endometrial cancer in combination with chemotherapy, but an unsurprisingly narrow label means rival Merck & Co.’s Keytruda could still make a splash in this indication.  

pink paper cut out of uterus
There Are 60,000 New Cases Of Endometrial Cancer Each Year In the US • Source: Shutterstock
Key Takeaways:

  • The label is limited to in mismatch repair deficient or microsatellite instability-high disease.

  • Rival Keytruda has shown efficacy in the broader proficient mismatch repair population.

  • GSK could still seek a broader label, but Keytruda’s reputation is likely to sway physicians.

GSK plc’s Jemperli has received a US Food and Drug Administration green light for use with chemotherapy in mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) first-line endometrial cancer earlier than expected,

Jemperli (dostarlimab) first won US approval in 2021 for second-line treatment of patients with dMMR recurrent or advanced endometrial cancer, with a subsequent label

More from New Products

More from Scrip

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.